"The successful completion of this transaction underscores our ongoing
commitment to becoming a global leader in oncology by delivering novel
therapies that improve the standards of care for patients. Additionally, the
Millennium clinical trial programs for irritable bowel disease (IBD) will
enhance our GI franchise. We look forward to a successful transition by
working closely with the talented Millennium employees now that they are part
of Takeda," said
"As part of the Takeda Group, Millennium will continue its commitment to
developing breakthrough medicines that will benefit patients around the world.
Millennium is excited to serve as Takeda's global center for oncology as we
work with our new colleagues at Takeda to drive scientific excellence and
create a world-class pipeline and products," said
As a result of the merger, each outstanding share of Millennium common
stock not validly tendered and accepted for payment in the tender offer (other
than any shares in respect of which appraisal rights are validly exercised
under
UBS Investment Bank acted as exclusive financial advisor and Edwards Angell Palmer & Dodge LLP acted as legal advisor to Takeda. Goldman, Sachs & Co. acted as exclusive financial advisor and WilmerHale acted as legal advisor to Millennium.
Cancellation of Millennium's 2008 Annual Meeting of Stockholders
Millennium also announced today that, as a result of its acquisition by
Takeda, the 2008 annual meeting of stockholders, previously scheduled for
About Takeda
Founded in 1781 and located in
About Millennium
Millennium, a Takeda Company, and a leading biopharmaceutical company
based in
Forward-Looking Statements This press release contains "forward-looking statements" that involve significant risks and uncertainties. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including: any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause results to differ from expectations include: Takeda's ability to successfully integrate the two companies and their products; customer acceptance of the companies' combined products, Takeda's ability to retain key employees; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, licensees, other business partners or governmental entities; other business effects, including the effects of industry, economic or political conditions outside of Millennium's or Takeda's control; transaction costs; actual or contingent liabilities; and other risks and uncertainties discussed in documents filed with the U.S. Securities and Exchange Commission by Millennium, as well as the tender offer documents filed by Mahogany Acquisition Corp. and the Solicitation/Recommendation Statement filed by Millennium. Neither Millennium nor Takeda undertakes any obligation to update any forward-looking statements as a result of new information, future developments or otherwise.
SOURCE Takeda Pharmaceutical Company Limited